Incuron, LLC is developing novel anti-cancer medicines called Curaxins, which are small molecules that target three key signaling pathways in cancer cells. The company aims to develop Curaxins for the Russian and international markets. Curaxin CBL0137 has shown efficacy against various tumors in animal models and is currently in Phase 1 clinical trials in Russia and the US. Curaxin CBL0102 has completed Phase 1B trials in Russia. The company is also developing analogs of CBL0137 and plans to finance preclinical and clinical development through 2022 to bring these innovative medicines to market.